Aktienanalyse zu Mustang Bio Inc (MBIO)MBIOMustang Bio Inc

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs into potential cures for cancers and autoimmune diseases. The Company has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR T) therapies. Its pipeline is focused in two core areas: CAR T therapies for autoimmune diseases and hematologic malignancies and CAR T therapies for solid tumors. It is developing a CAR T therapy for hematologic malignancies and autoimmune diseases in partnership with Fred Hutchinson Cancer Center targeting CD20 and for solid tumors in partnership with City of Hope National Medical Center targeting IL13Ra2. It has also partnered with Nationwide Children’s Hospital for a herpes simplex virus type 1 oncolytic virus to enhance the activity of MB-101 for the treatment of patients with high-grade malignant brain tumors. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Mustang Bio Inc is not a good buy right now due to its significant financial losses and poor performance metrics. The stock is currently priced at $0.39, down 63.12% year-to-date, and has a negative forward P/E ratio of 0, indicating no expected earnings growth. Additionally, the company's gross profit has been consistently negative, with a reported net income loss of $1,072,000 in Q2 2026. The main risk is its high volatility and lack of profitability, as evidenced by a 52-week low of $0.35, which is very close to its current price.

1 analysts cover MBIO: 1 rate it Buy, 0 Hold and 0 Sell.